Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study
用户EO9nReo4Hj6s
1个月前
66
10
已完结
1. 系统已在2026-01-28 17:57:03对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.lungcan.2025.108633
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0169500225005252
其他信息:
出版社: Elsevier BV
作者: Yoshitaka Zenke; Seiji Niho; Yukihiro Toi; Masafumi Yamaguchi; Satoshi Hara; Yuki Akazawa; Yukio Hosomi; Kimio Yonesaka; Hiroaki Akamatsu; Toshihide Yokoyama; Junko Tanizaki; Kiyonobu Ueno; Hiroshi Gyotoku; Toshihiro Misumi; Kazuhiko Nakagawa; Nobuyuki Yamamoto; Masahiro Tsuboi
